Evidence map›Paper›PMID 25977841›Full record

ArticleJournal of pulmonary & respiratory medicine2014

Mortality of Hospitalized Patients with Pleural Effusions.

Anna S Kookoolis, Jonathan T Puchalski, Terrence E Murphy, Katy Lb Araujo, Margaret A Pisani

Open access · bronzeAbstract read
In one paragraph

Article in Journal of pulmonary & respiratory medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Why do patients with cancer die?Nature reviews. Cancer · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Pleural macrophages translocate to the lung during infection to promote improved influenza outcomes.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  10. Article
  11. Article
  12. Percutaneous Chest Tube for Pleural Effusion and Pneumothorax.Seminars in interventional radiology · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Sarcopenia in patients with malignant pleural effusion: impact on symptoms, health status, and response to hospitalization.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
    Observational
  17. Observational
  18. Patient-Centered Outcomes Following Thoracentesis.Pleura (Thousand Oaks, Ventura County, Calif.)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Anna S KookoolisPulmonary, Critical Care Medicine, Yale University School of Medicine, USA ; Interventional Program (IP), Yale University School of Medicine, USA.
Jonathan T PuchalskiPulmonary, Critical Care Medicine, Yale University School of Medicine, USA ; Interventional Program (IP), Yale University School of Medicine, USA.
Terrence E MurphyClaude D. Pepper Older Americans Independence Center at Yale, Program on Aging, Yale University School of Medicine, USA.
Katy Lb AraujoClaude D. Pepper Older Americans Independence Center at Yale, Program on Aging, Yale University School of Medicine, USA.
Margaret A PisaniPulmonary, Critical Care Medicine, Yale University School of Medicine, USA.
Yale University · US

Funding

Yale Study Support Suite (YES3): Dashboard and Web Portal Software Supporting Research Workflow through integrated, customizable REDCap External ModulesP30AG021342 · NIA · YALE UNIVERSITY · PI Denise Esserman · 2002 to 2026
$37.9M
NIA NIH HHS P30 AG021342
6 · The paper itself

Abstract

backgroundEach year in the United States an estimated 1.5 million people develop pleural effusions and approximately 178,000 thoracenteses (12%) are performed. While it has been established that malignant effusions are associated with increased mortality, the association between mortality and all-cause pleural effusions in a medical population has not been previously evaluated. Our objective was to evaluate associations between 30-day and 12-month all-cause mortality among patients with a pleural effusion.

methodsAll patients admitted to the medical service at Yale-New Haven Hospital during March 2011 were screened for pleural effusion. Pleural effusions were documented by the attending radiologist and the medical record was reviewed for admitting diagnosis, severity of illness and whether a thoracenteses was performed. The outcomes were 30-day and 12-month mortality after identification of the pleural effusion.

resultsOne-hundred and four patients admitted to the medical service had pleural effusions documented by the attending radiologist. At 30-days, 15% of these patients had died and by 12-months mortality had increased to 32%. Eleven (10.6%) of the 104 patients underwent a thoracenteses. Severity of illness and malignancy were associated with 30-day mortality. For 12-month mortality, associations were found with age, severity of illness, malignancy, and diagnosis of pulmonary disease. Although sample size precluded statistical significance with mortality, the hazard ratio for thoracenteses and 30-day mortality was protective, suggesting a possible short term survival benefit.

conclusionsIn hospitalized medical patients with a pleural effusion, age, severity of illness and malignancy or pulmonary disease were associated with higher 12-month mortality. Thoracenteses may provide a protective effect in the first 30 days, but larger studies are needed to detect a short-term survival benefit. The presence of a pleural effusion indicates a high risk of death, with 15% of patients dying within 30 days and 32% dead within one-year of hospital admission.

Indexed as

MortalityPleural effusionThoracenteses

Identifiers

PMID25977841
PMCPMC4428160
OpenAlexW2317891791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.